237 related articles for article (PubMed ID: 32974156)
1. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling.
Zhou X; Qiu S; Nie L; Jin D; Jin K; Zheng X; Yang L; Wei Q
Front Oncol; 2020; 10():1429. PubMed ID: 32974156
[TBL] [Abstract][Full Text] [Related]
2. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
3. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
4. LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.
Zheng X; Liao X; Nie L; Lin T; Xu H; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Cell Dev Biol; 2021; 9():748280. PubMed ID: 35004669
[No Abstract] [Full Text] [Related]
5. Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling.
Yu J; Xie M; Ge S; Chai P; Zhou Y; Ruan J
Front Oncol; 2020; 10():580029. PubMed ID: 33330057
[TBL] [Abstract][Full Text] [Related]
6. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
7. Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer.
Li J; Lou Y; Li S; Sheng F; Liu S; Du E; Zhang Z
Front Mol Biosci; 2020; 7():598599. PubMed ID: 33604353
[TBL] [Abstract][Full Text] [Related]
8. A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.
Zheng X; Zhou X; Xu H; Jin D; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Genet; 2021; 12():764184. PubMed ID: 34899849
[TBL] [Abstract][Full Text] [Related]
9. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
[TBL] [Abstract][Full Text] [Related]
10. Stromal LAG-3
Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
[TBL] [Abstract][Full Text] [Related]
11. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
12. A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscle-invasive bladder cancer.
Wang X; Pan L; Lu Q; Huang H; Feng C; Tao Y; Li Z; Hu J; Lai Z; Wang Q; Tang Z; Xie Y; Li T
J Clin Lab Anal; 2021 May; 35(5):e23754. PubMed ID: 33813769
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
14. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
[TBL] [Abstract][Full Text] [Related]
15. Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma.
Wang L; Yuan W; Li L; Shen Z; Geng Q; Zheng Y; Zhao J
J Immunol Res; 2022; 2022():9544827. PubMed ID: 35983077
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
[TBL] [Abstract][Full Text] [Related]
17. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
18. An immunogenomic signature for molecular classification in hepatocellular carcinoma.
Zhuang W; Sun H; Zhang S; Zhou Y; Weng W; Wu B; Ye T; Huang W; Lin Z; Shi L; Shi K
Mol Ther Nucleic Acids; 2021 Sep; 25():105-115. PubMed ID: 34401208
[TBL] [Abstract][Full Text] [Related]
19. Classification of serous ovarian carcinoma based on immunogenomic profiling.
Chen P; Zhang Y; Liang C; Yang Y; Li Y; Wan J
Int Immunopharmacol; 2021 Feb; 91():107274. PubMed ID: 33360087
[TBL] [Abstract][Full Text] [Related]
20. Integration of CD4
Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Liu H; Chang Y; Zhu Y; Xu L; Wang Z; Wang Y; Zhang W
Cancer Sci; 2024 Apr; 115(4):1306-1316. PubMed ID: 38402640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
